GlassScriptPhysician profile
Roger D Duber
NPI 1942261904
$4,062.95
in general payments reported to CMS, 2019-2025
36 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $410 · 2021: $659 · 2022: $556 · 2023: $318 · 2024: $889 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554 · Entertainment: $15.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.27 |
| Entertainment | $15.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $623.00 | 2019-2025 | Lithovue Empower, Sentinel, Mylux Patient Kit With Mobile Device |
| Abiomed | $578.67 | 2019-2024 | Impella |
| Pfizer INC. | $309.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $303.61 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $279.98 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $169.54 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $167.27 | 2019-2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $164.90 | 2019-2024 | |
| Amgen INC. | $157.49 | 2019-2025 | Repatha, Repatha |
| Cmp Pharma, INC. | $144.96 | 2021 | |
| Abbott Laboratories | $135.73 | 2019-2021 | |
| Esperion Therapeutics, INC. | $88.56 | 2022-2024 | Nexletol |
| Gilead Sciences, INC. | $79.52 | 2019 | |
| Kestra Medical Technology Services, INC. | $77.49 | 2022-2024 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $76.22 | 2020-2025 | Farxiga |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $64.88 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.36 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $58.61 | 2024 | Arcalyst |
| Heartflow, INC. | $52.31 | 2020 | |
| Medtronic Vascular, INC. | $49.92 | 2019-2020 | |
| Astellas Pharma US INC | $47.86 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $39.68 | 2025 | Verquvo |
| Portola Pharmaceuticals, LLC | $39.66 | 2019 | |
| Preventice Services, LLC | $37.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $36.71 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $27.89 | 2021 | |
| Altathera Pharmaceuticals LLC | $27.11 | 2025 | Sotalol Hydrochloride |
| Kiniksa Pharmaceuticals, LTD. | $21.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.55 | 2024 | |
| Edwards Lifesciences Corporation | $21.54 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biotronik INC. | $17.78 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.91 | 2020 | |
| Scpharmaceuticals INC. | $16.40 | 2023 | |
| Cordis US Corp. | $16.37 | 2024 | Mynx Control |
| Opsens INC. | $15.19 | 2023 | Optowire |
| Amarin Pharma, INC. | $14.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Duber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.